For research use only. Not for use in humans.

Mipasetamab (Anti-AXL / UFO)

Synonyms: null

Mipasetamab (Anti-AXL / UFO) is a human monoclonal IgG1κ antibody targeting AXL, a tyrosine kinase receptor, and an TAM receptor, which involves the synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). MW: 145.78 kD.

Mipasetamab (Anti-AXL / UFO)

Quality Control

Batch: A277401 Purity: 99% Protein concentration: Endotoxin Level: <1EU/mg
99

Specificity

Name Citation Axl Others
BMS-777607 62 RON,Met,Tyro3
Bemcentinib (R428) 131
XL092 0 VEGFR2,MER,MET
UNC2025 7 FLT3,Mer,TrkA
Ningetinib 0 VEGFR2,c-Met
Tamnorzatinib (ONO-7475) 4 Mer,FLT3
RU-301 0
Sitravatinib (MGCD516) 6 DDR2,EPHA3,Mer
CEP-40783 (RXDX-106) 7 c-Met,Tyro3,MER
S49076 1 Met,Mer,FGFR3
Merestinib (LY2801653) 10 DDR1,Met,DDR2
SGI-7079 4 YES,Mer,Met
UNC2025 HCl 9 Mer,FLT3,Tyro3
Dubermatinib(TP-0903) 19
NPS-1034 3 Met
LDC1267 9 Mer,Tyro3
PF-07265807 0 Mer
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Mipasetamab (Anti-AXL / UFO) is a human monoclonal IgG1κ antibody targeting AXL, a tyrosine kinase receptor, and an TAM receptor, which involves the synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). MW: 145.78 kD.
References

Product Details

CAS No. 2361055-48-1
Molecular Weight 145.78
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.